Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

4.8K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
4.8K
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

10.4K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
10.4K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

88.3K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
88.3K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

532
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
532
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

4.0K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
4.0K
Spare Receptors01:30

Spare Receptors

4.8K
Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quality of Life in Patients with Osteoporotic Vertebral Compression Fractures.

Journal of bone metabolism·2017
Same author

Response to: Comparison of Posterior Lumbar Interbody Fusion and Posterolateral Lumbar Fusion in Monosegmental Vacuum Phenomenon within an Intervertebral Disc.

Asian spine journal·2016
Same author

Predictors of reduction loss in tibial plateau fracture surgery: Focusing on posterior coronal fractures.

Injury·2016
Same author

Comparison of Posterior Lumbar Interbody Fusion and Posterolateral Lumbar Fusion in Monosegmental Vacuum Phenomenon within an Intervertebral Disc.

Asian spine journal·2016
Same author

The factors affecting stiffness occurring with rotator cuff tear.

Journal of shoulder and elbow surgery·2011
Same author

Treatment recommendations for idiopathic scoliosis: an assessment of the Lenke classification.

Spine·2003

Related Experiment Video

Updated: Mar 15, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

13.0K

Selective Estrogen Receptor Modulators.

Ki-Chan An1

  • 1Department of Orthopaedic Surgery, Busan Paik Hospital College of Medicine, Inje University, Busan, Korea.

Asian Spine Journal
|August 26, 2016
PubMed
Summary
This summary is machine-generated.

Selective estrogen receptor modulators (SERMs) offer dual estrogen effects for treating breast cancer and osteoporosis. Raloxifene is a key SERM, with ongoing research comparing its benefits against newer agents like bazedoxifene.

Keywords:
OsteoporosisSelective estrogen receptor modulators

More Related Videos

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay
06:07

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Published on: June 7, 2020

5.4K
Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

11.0K

Related Experiment Videos

Last Updated: Mar 15, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

13.0K
Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay
06:07

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Published on: June 7, 2020

5.4K
Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

11.0K

Area of Science:

  • Pharmacology
  • Oncology
  • Endocrinology

Background:

  • Selective estrogen receptor modulators (SERMs) exhibit tissue-specific estrogen agonist/antagonist activity.
  • SERMs are utilized in treating breast cancer, osteoporosis, and postmenopausal symptoms.
  • Endometrial safety is a critical differentiator among SERMs like tamoxifen, raloxifene, lasofoxifene, and bazedoxifene.

Purpose of the Study:

  • To review the therapeutic applications of SERMs.
  • To highlight the role of SERMs in managing osteoporosis and reducing breast cancer incidence.
  • To discuss the comparative advantages and ongoing research of raloxifene and bazedoxifene.

Main Methods:

  • Literature review of SERM applications.
  • Analysis of clinical data on SERM efficacy and safety.
  • Comparative assessment of raloxifene and bazedoxifene.

Main Results:

  • SERMs effectively reduce invasive breast cancer incidence in postmenopausal women.
  • Raloxifene is established for osteoporosis prevention and treatment.
  • Comparative studies are evaluating raloxifene against bazedoxifene.

Conclusions:

  • SERMs represent a valuable therapeutic class for postmenopausal health.
  • Raloxifene remains a significant agent, with newer SERMs like bazedoxifene showing promise.
  • Long-term safety studies are crucial for SERM-based osteoporosis treatment.